Merck Revenue 2010-2023 | MRK
Merck annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Merck revenue for the quarter ending December 31, 2023 was $14.631B, a 5.79% increase year-over-year.
- Merck revenue for the twelve months ending December 31, 2023 was $60.115B, a 1.4% increase year-over-year.
- Merck annual revenue for 2023 was $60.115B, a 1.4% increase from 2022.
- Merck annual revenue for 2022 was $59.283B, a 21.72% increase from 2021.
- Merck annual revenue for 2021 was $48.704B, a 17.31% increase from 2020.
Merck Annual Revenue
(Millions of US $) |
| 2023 |
$60,115 |
| 2022 |
$59,283 |
| 2021 |
$48,704 |
| 2020 |
$41,518 |
| 2019 |
$39,121 |
| 2018 |
$42,294 |
| 2017 |
$40,122 |
| 2016 |
$39,807 |
| 2015 |
$39,498 |
| 2014 |
$42,237 |
| 2013 |
$44,033 |
| 2012 |
$47,267 |
| 2011 |
$48,047 |
| 2010 |
$45,987 |
| 2009 |
$27,428 |
Merck Quarterly Revenue
(Millions of US $) |
| 2023-12-31 |
$14,631 |
| 2023-09-30 |
$15,962 |
| 2023-06-30 |
$15,035 |
| 2023-03-31 |
$14,487 |
| 2022-12-31 |
$13,830 |
| 2022-09-30 |
$14,959 |
| 2022-06-30 |
$14,593 |
| 2022-03-31 |
$15,901 |
| 2021-12-31 |
$13,521 |
| 2021-09-30 |
$13,154 |
| 2021-06-30 |
$11,402 |
| 2021-03-31 |
$10,627 |
| 2020-12-31 |
$9,179 |
| 2020-09-30 |
$10,929 |
| 2020-06-30 |
$9,353 |
| 2020-03-31 |
$12,057 |
| 2019-12-31 |
$4,148 |
| 2019-09-30 |
$12,397 |
| 2019-06-30 |
$11,760 |
| 2019-03-31 |
$10,816 |
| 2018-12-31 |
$10,998 |
| 2018-09-30 |
$10,794 |
| 2018-06-30 |
$10,465 |
| 2018-03-31 |
$10,037 |
| 2017-12-31 |
$10,433 |
| 2017-09-30 |
$10,325 |
| 2017-06-30 |
$9,930 |
| 2017-03-31 |
$9,434 |
| 2016-12-31 |
$10,115 |
| 2016-09-30 |
$10,536 |
| 2016-06-30 |
$9,844 |
| 2016-03-31 |
$9,312 |
| 2015-12-31 |
$10,215 |
| 2015-09-30 |
$10,073 |
| 2015-06-30 |
$9,785 |
| 2015-03-31 |
$9,425 |
| 2014-12-31 |
$10,482 |
| 2014-09-30 |
$10,557 |
| 2014-06-30 |
$10,934 |
| 2014-03-31 |
$10,264 |
| 2013-12-31 |
$11,320 |
| 2013-09-30 |
$11,032 |
| 2013-06-30 |
$11,010 |
| 2013-03-31 |
$10,671 |
| 2012-12-31 |
$11,737 |
| 2012-09-30 |
$11,488 |
| 2012-06-30 |
$12,311 |
| 2012-03-31 |
$11,731 |
| 2011-12-31 |
$12,294 |
| 2011-09-30 |
$12,022 |
| 2011-06-30 |
$12,151 |
| 2011-03-31 |
$11,580 |
| 2010-12-31 |
$12,094 |
| 2010-09-30 |
$11,125 |
| 2010-06-30 |
$11,346 |
| 2010-03-31 |
$11,422 |
| 2009-12-31 |
$10,093 |
| 2009-09-30 |
$6,050 |
| 2009-06-30 |
$5,900 |
| 2009-03-31 |
$5,385 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$317.566B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
